Clinical trials: sponsored by Eli Lilly and Company
Ulcerative Colitis
A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)
This study was designed to evaluate how the body processes and removes mirikizumab. The study also evaluated safety and disease response in pediatric participants with UC taking mirikizumab.
- Trial name
- SHINE-1 (NCT04004611)
- Testing
- Mirikizumab
- Where
- 37 sites in United States, Canada and 3 more
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Healthy
A Study of LY3154885 in Healthy Participants
The main purpose of this study is to learn more about the safety and side effects of LY3154885 when given by mouth to healthy participants. The study will have up to four parts. Each participant will enroll in only one part.
- Trial name
- NCT04014361
- Testing
- LY3154885 - Capsule, Itraconazole, LY3154885 - Tablet
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Mirikizumab (LY3074828) Injection in Healthy Participants
This study is conducted to compare how much mirikizumab, in two different formulations, is absorbed into the bloodstream and how long the body takes to get rid of it, when given as an injection under the skin or into the veins.
- Trial name
- NCT03053622
- Testing
- Mirikizumab Test, Mirikizumab Reference
- Where
- United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of LY3074828 in Healthy Participants
The purpose of this study is to look at the amount of the study drug, LY3074828, that gets into the blood stream and how long it takes the body to get rid of LY3074828, when given as a solution formulation in different devices.
- Trial name
- NCT03456713
- Testing
- LY3074828
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Mirikizumab in Healthy Participants
The main purpose of this study is to compare the amount of mirikizumab that gets into the blood stream and how long it takes the body to get rid of it, when given as a solution formulation via manual prefilled syringe or…
- Trial name
- NCT04607733
- Testing
- Mirikizumab Prefilled Syringe, Mirikizumab Autoinjector
- Where
- 4 sites in United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Injections of LY3074828 in Healthy Participants
The purpose of this study is to learn about the effects of LY3074828 when given as an injection just under the skin by two different devices. The study will last about 12 weeks for each participant.
- Trial name
- NCT03886948
- Testing
- LY3074828, Pre-filled syringe (PFS), Autoinjector (AI)
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India
The reason for this study is to see if insulin glargine is safe in participants with type 2 diabetes mellitus (T2DM) in India.
- Trial name
- NCT04153981
- Testing
- Insulin Glargine
- Where
- 11 sites in India
- Volunteers
- 304 people
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Mirikizumab (LY3074828) in Healthy Participants
The main purpose of this study is to explore the safety and tolerability of mirikizumab in healthy Japanese and Caucasian participants.
- Trial name
- NCT02568423
- Testing
- Mirikizumab - IV, Mirikizumab - SC
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity
A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide
This is a study of tirzepatide in participants with obesity. The main purpose is to learn more about how tirzepatide affects the number of calories participants burn and the amount of food they eat.
- Trial name
- NCT04081337
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Tirzepatide (LY3298176) in Healthy Participants
This study has four parts. Each participant will enroll in one part. Part A: The purpose of Part A is to compare study drug tirzepatide solution formulation to a powder formulation mixed with water and given subcutaneously (SC)…
- Trial name
- NCT03375463
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer
A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer
The main purpose of this study is to evaluate the safety of ramucirumab or necitumumab in combination with osimertinib in participants with non-small cell lung cancer (NSCLC).
- Trial name
- NCT02789345
- Testing
- Ramucirumab, Necitumumab, Osimertinib
- Where
- 11 sites in United States, France and 3 more
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Lasmiditan in Healthy Volunteers
The main purpose of the study is to investigate the blood concentrations of dabigatran etexilate and rosuvastatin when taken alone compared to when taken together with lasmiditan in healthy participants.
- Trial name
- NCT04749914
- Testing
- Lasmiditan, Dabigatran Etexilate, Rosuvastatin
- Where
- Singapore
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Psoriasis
A Study of Mirikizumab in Participants With Plaque Psoriasis
This study is known as a "drug interaction study." The purpose is to learn how commonly used drugs or substances (midazolam, warfarin, dextromethorphan, omeprazole, and caffeine) and their breakdown products get into the…
- Trial name
- NCT03718884
- Testing
- Drug Cocktail, Mirikizumab
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Mirikizumab in Healthy Chinese Participants
The main purpose of this study is to evaluate the safety of the study drug known as mirikizumab. The study will investigate how the body processes the study drug. It will last up to about 4 months for each participant.
- Trial name
- NCT04137380
- Testing
- Mirikizumab - IV, Mirikizumab - SC
- Where
- 2 sites in China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study to Compare Two Different Formulations of Mirikizumab in Healthy Participants
The purpose of this study is to compare two different formulations of mirikizumab in healthy participants. This study will compare how much of each formulation gets into the blood stream and how long it takes the body to remove…
- Trial name
- NCT04548219
- Testing
- Mirikizumab
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Two Formulations of LY3074828 in Healthy Participants
The purpose of this study is to look at the amount of the study drug, LY3074828, that gets into the blood stream and how long it takes the body to get rid of LY3074828 when given as different formulations.
- Trial name
- NCT03662100
- Testing
- LY3074828, Auto-injector (AI), Prefilled syringe (PFS)
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Two Different Formulations of LY3074828 in Healthy Participants
The purpose of this study is to look at the amount of the study drug, LY3074828, that gets into the blood stream and how long it takes the body to get rid of LY3074828 when given as different formulations.
- Trial name
- NCT03188510
- Testing
- LY3074828
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)
This is a study of tirzepatide in Chinese participants without Type 2 Diabetes who have obesity or overweight. The main purpose is to learn more about how tirzepatide affects body weight.
- Conditions
- Obesity, Overweight, Metabolism and Nutrition Disorder
- Trial name
- SURMOUNT-CN (NCT05024032)
- Testing
- Tirzepatide
- Where
- 29 sites in China
- Volunteers
- 210 people
- Sponsor
- Eli Lilly and Company
Healthy, Type 2 Diabetes Mellitus (T2DM)
A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)
The main purposes of this study are to determine: The safety of tirzepatide and any side effects that might be associated with it. How much tirzepatide gets into the bloodstream and how long it takes the body to get rid of it.
- Trial name
- NCT02759107
- Testing
- Tirzepatide, Dulaglutide
- Where
- 2 sites in United States, Singapore
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide
The purpose of this study is to learn more about how tirzepatide affects stomach emptying in overweight/very overweight participants. Participants include those without diabetes and those with type 2 diabetes.
- Conditions
- Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT04407234
- Testing
- Tirzepatide, Acetaminophen
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.